Quarterly report pursuant to Section 13 or 15(d)

SETTLEMENT LIABILITY (Details Narrative)

v3.24.1.1.u2
SETTLEMENT LIABILITY (Details Narrative) - USD ($)
$ in Thousands
Nov. 12, 2021
Mar. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]      
Long term debt   $ 18,079
REGENXBIO [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Settlement liabilities, current $ 30,000    
Loss contingency settlement agreement terms (1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.    
Effective interest rate stated percentage   9.60%  
REGENXBIO [Member] | Due in November 2024 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Long term debt   $ 4,700 $ 4,600